Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

SNDX-5613 with Decitabine/Cedazuridine, and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, SAVE Trial

Trial Status: active

This phase I/II trial studies the side effects and best dose of SNDX-5613 and to see how well it works in combination with decitabine/cedazuridine and venetoclax in treating patients with acute myeloid leukemia that has come back (relapsed) or does not respond to treatment (refractory). SNDX-5613 blocks signals passed from one molecule to another inside a cell. Blocking these signals can affect many functions of the cell, including cell division and cell death, and may kill cancer cells. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have a greater effect. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving SNDX-5613 with decitabine/cedazuridine and venetoclax may help control acute myeloid leukemia.